Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study
Uwe Zeymer
REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.
